Live Breaking News & Updates on ஜெநெடிக் அறிவியல் பிரிவு இல் தெர்மோ மீனவர் அறிவியல்

(NASDAQ:PRPO) announces that Mr. Ron Andrews has joined the company s Board of Directors. As the company continues to build its products division around commercializing the technologies it has developed (such as HemeScreen and IV-cell), having additional resources and experienced industry veterans to support management s goals is key to its success and ongoing growth.
Mr. Andrews brings a wealth of experience in the diagnostics world, and specifically in the areas of product development & commercialization. Some of Mr. Andrews past experiences includes Chief Commercial Officer at Roche Molecular; President of Genetic Science Division at Thermo Fisher Scientific; President of the Medical Sciences Venture at Life Technologies Corporation; and CEO of Clarient, which was acquired by GE Healthcare for $580M in 2010. ....

Mark Rimer , Ron Andrews , Ilan Danieli , Yale School Of Medicine , Partner At Kuzari Group , Harvard Dana Farber Cancer Institute , Exchange Commission , Precipio Inc , Sciences Venture At Life Technologies Corporation , Kuzari Group , Genetic Science Division At Thermo Fisher Scientific , Securities Exchange , University Of Pennsylvania , Ge Healthcare , Chief Commercial Officer , Roche Molecular , Genetic Science Division , Thermo Fisher Scientific , Medical Sciences Venture , Life Technologies Corporation , Yale School , Dana Farber Cancer Institute , Securities Act , Securities Exchange Act , Annual Report , குறி றிமேற் ,